Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by an
educational grant from
Novartis Pharmaceuticals Corporation
Psoriatic arthritis is a debilitating disease that may affect up to
1 million adults in the United States, affecting men and women
equally. Psoriatic arthritis is a progressive, inflammatory disease
that is associated with a number of dermatologic and musculoskeletal
manifestations. Patients can experience extreme pain and joint
damage that may affect their quality of life, physical function, and
ability to work. Symptoms include fatigue, joint inflammation, and
potentially progressive joint damage. Diagnosing psoriatic arthritis
can be very complex with the most critical factor being the absence
of validated criteria for identifying and classifying cases that
will help diagnose the disease. The standard diagnostic measures are
based on history, a physical exam and x-ray features, so
establishing the presence of characteristic signs and symptoms
associated in both the skin and joints, and by ruling out more
common inflammatory arthritis, can be very helpful.
The past few years have seen a number of treatments introduced for
psoriatic arthritis. Along with symptomatic treatments, such as
nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and
local corticosteroid injections into joints, there are also the oral
small molecules (OSMs) for treatment. The Tumor Necrosis Factor (TNF)
inhibitors have been available for nearly 20 years and continue to
be a viable option for patients. More recently key cytokines in the
psoriatic disease pathophysiology have been introduced and they
include Janus kinases and signal transducers and activators of
transcription (JAK-STATs) as well as are the interleukin (IL)-12,
IL-17, IL-22 and IL-23 pathway inhibitors. These newer biologic
treatments target some of these key cytokines to treat psoriatic
disease. Clinicians need to be able to incorporate these new
approaches into treatment paradigms, considering both safety and
efficacy, by being educated with appropriate management strategies
that will guide treatment decisions for patients with psoriatic
Upon completion of this
activity, participants will be able to:
Analyze current evidence and
guidelines to inform treatment decisions for patients with
psoriatic arthritis (PsA)
Assess screening and assessment
strategies to diagnose patients with PsA
Explore immunological targets of
current and emerging immune-based therapies, including the
safety and efficacy data for each
Discuss the strategies to overcome
barriers related to comorbidities as well as their implication
on the choice of treatment
Implement comprehensive and
multidisciplinary approaches to treating PsA, including
strategies to engage the patient
||Atul A. Deodhar, MD,
MRCP, FACR, FACP
Professor of Medicine
Medical Director of Rheumatology Clinics
Division of Arthritis & Rheumatic Diseases
Oregon Health & Science University
serves as a consultant and on an advisory board for
AbbVie, Amgen, Boeheringer Ingelheim, Bristol Myers
Squibb, Celgene, Eli Lilly, Galapagos, Gilead, Janssen,
Novartis, Pfizer, and UCB. He has received
grants/research support from AbbVie, Boeheringer
Ingelheim, Eli Lilly, Novartis, Pfizer, and UCB. His
presentation has been peer reviewed for any bias.
MD has no real or perceived financial relationships to
Jeremy Williams has no real or perceived financial
relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived
financial relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
This activity is supported by
an educational grant from
Novartis Pharmaceuticals Corporation
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue